Safety and Efficacy of a Neonatal Fc Receptor Antagonist in Patients With Anti‐<scp>NMDAR</scp> Encephalitis
In this exploratory study, efgartigimod demonstrated a favorable safety profile for patients with anti-NMDAR encephalitis and appeared to facilitate the recovery of clinical symptoms and neurological function. However, further prospective randomized studies with larger patient cohorts are necessary to confirm the safety and efficacy of efgartigimod.
Authors
- Bingjun Zhang (ORCID: https://orcid.org/0000-0002-9641-2485)
- Fuhua Peng (ORCID: https://orcid.org/0000-0001-7500-205X)
- Han Cai (ORCID: https://orcid.org/0000-0001-8509-6854)
- Zhihong Bian
- Wei Qiu (ORCID: https://orcid.org/0000-0001-8102-8192)
- Zhengqi Lu (ORCID: https://orcid.org/0000-0002-2118-0368)
- Haotian Wu (ORCID: https://orcid.org/0000-0002-6271-0249)
- Yanfang Zuo
- Ping Liu (ORCID: https://orcid.org/0009-0009-8706-0252)
Institutions
- Sun Yat-sen University (CN)
- Longgang Central Hospital (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- CNS Neuroscience & Therapeutics
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1111/cns.70534
- Citations
- 4
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.56
Funders
- Sun Yat-sen University